U.S. Markets close in 2 hrs 24 mins

Alchemia Limited (ACL.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.009-0.001 (-10.000%)
At close: 1:08PM AEST

Alchemia Limited

100 Albert Road
Level 4
South Melbourne, VIC 3205
61 3 9692 7222

Full Time Employees

Key Executives

Ms. Melanie Jaye Leydin B.Bus (Acc/Law), CAChief Financial Officer and Company Sec.54.5kN/A44
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Alchemia Limited, a biopharmaceutical company, engages in developing oncology products. It provides Fondaparinux sodium, a generic anti-coagulant drug. The company also offers HyACT, a platform technology that targets cancer drugs directly to tumours, designed to increase effectiveness against tumours without increasing toxicity. In addition, its lead product candidate is HA-Irinotecan, an off-patent chemotherapy drug, which is used in the treatment of metastatic colorectal cancer. The company develops HA-Doxorubicin that has completed a Phase I/IIa clinical trial in patients with metastatic cancers; monoclonal antibodies; and anticancer compounds through active transport to cancer cells through the CD44 receptor. Alchemia Limited was founded in 1995 and is headquartered in South Melbourne, Australia.

Corporate Governance

Alchemia Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.